REVIEWS |
|
O.D. Ostroumova (1, 2), I.V. Goloborodova (2)
Hypoglycemic drugs and drug-induced heart failure
|
10-21 |
|
A.F. Verbovoy, I.A. Tsanava, N.I Verbovaya., Yu.A. Dolgikh
The polymorbidity and hypothyroidism
|
22-28 |
|
M.V. Leonova
Statins and the risk of diabetes: an evidence-based review
|
30-38 |
|
A.F. Verbovoy, I.A. Tsanava
The importance of adipokines in clinical practice
|
40-46 |
ORIGINAL ARTICLES |
|
N.A. Demidov (1), O.M. Koteshkova (2), M.A. Balberova (3), M.B. Antsiferov (2)
Start of therapy of type 2 diabetes mellitus with a fixed combination. Metformin with vildagliptin or glibenclamide, is there any difference?
|
47-53 |
|
M.B. Antsiferov (1), N.A. Demidov (2)
Experience in the integrated use of organizational approaches and clinical tools to achieve glycemic control goals
|
54-58 |
|
N.A. Demidov (1), M.A. Balberova (2), M.B. Antsiferov (3)
What can affect the effectiveness of basal insulin therapy for patients with type 2 diabetes mellitus: analysis of the results of real clinical practice according to the diabetes register
|
60-66 |
|
N.V. Vorokhobina (1), Y.S. Lovkova (2), A.V. Kuznetsova (1), Y.V. Kovalyova (1), N.V. Ivanov (1)
Risk of recurrent thyrotoxicosis and the incidence of obstetric complications in pregnant women with diffuse toxic goiter
|
67-73 |
|
|
O.D. Ostroumova (1, 2), V.O. Kachan (3), A.I. Kochetkov (1)
Drug-induced hyperthyroidism
|
74-80 |
|
A.S. Ametov (1), E.A. Tertychnaya (2)
Early pathogenetic combined therapy of sugar diabetes type 2: focus on insulin resistance
|
82-89 |
|
I.A. Ilovaiskaya (1, 2)
Difficult patient with acromegaly: expanding horizons of opportunities
|
90-95 |
Русский
